Table 1 Patient characteristics between MST and UCBT group

Sex, male (%)

65 (57.5)

20 (46.5)

0.28

Age (years), Median (Range)

25 (15–57)

34 (15–58)

0.002

Weight (kg), Median (Range)

60 (40–93)

62 (36–83.6)

0.26

ABO Incompatibility, n (%)

0.14

 Identical or minor incompatibility

68(60.2)

32 (74.4)

 Major or bidirectional incompatibility

45 (39.8)

11(25.6)

HLA matching (/6), n (%)

 < 0.001

 4

62 (54.9)

0 (0.0)

 5

47 (41.6)

0 (0.0)

 6

4 (3.5)

43 (100.0)

Donor/Receptor

1

 F/M

28 (24.8)

10 (23.3)

 Others

85 (75.2)

33 (76.7)

Conditioning (%)

0.28

 BU/CY2 based

70 (61.9)

22 (51.2)

 TBI/CY based

43 (38.1)

21 (48.8)

 Infusion TNC, Median (Range,10⁷/Kg)

2.7 (1.0–6.8)

74.4 (24.6–160.0)

 < 0.001

 Infusion CD34⁺, Median (Range,10⁵/Kg)

1.8 (0.1–7.8)

4.2 (1.4–57.8)

 < 0.001

Disease status before HSCT

0.25

 CR1

75 (66.4)

33 (76.7)

   ≥ CR2

38 (33.6)

10 (23.3)

Cytogenetics

0.36

 Normal, n (%)

53 (46.9)

21 (48.8)

 BCR/ABL, n (%)

40 (35.4)

20 (46.5)

 t(v;14q32), n (%)

5 (4.4)

1 (2.3)

 Complex karyotype, n (%)

3 (2.7)

0 (0.0)

 E2A/PBX1, n (%)

6 (5.3)

0 (0.0)

 HOX11 overexpression, n (%)

1 (0.9)

1 (2.3)

 Ph-like, n (%)

5 (4.4)

0 (0.0)

Cytogenetical Prognosis, n (%)

0.86

 Good^a

60 (53.1)

22 (51.2)

 Poor^b

53 (46.9)

21 (48.8)

Received CAR-T before HSCT, n (%)

7 (6.2)

0 (0.0)

0.19

Transplantation time

0.05

 2001–2016

42 (37.2)

24 (55.8)

 2017–2020

71 (62.8)

19 (44.2)

GVHD prophylaxis, n (%)

0.006

 CsA + MMF

112 (99.1)

38 (88.4)

 CsA + MMF + MTX

1 (0.9)

5 (11.6)

MRD

0.69

 Negative, n (%)

108 (95.6)

40 (93.0)

 Positive, n (%)

5 (4.4)

3 (7.0)

 Induction failure, n (%)

9 (8.0)

2 (4.7)

0.73

WBC at diagnosis

0.05

  ≤ 30 × 10⁹/L

76 (67.3)

36 (83.7)

  > 30 × 10⁹/L

37 (32.7)

7 (16.3)